Tech Tonics: Susan Desmond-Hellmann, The Inquisitive Leader

January 22nd, 2019 |
Image for FaceBook

 
Share this post:
Facebook | Twitter | Google+ | LinkedIn | Pinterest | Reddit | Email
 
This post can be linked to directly with the following short URL:


 
The audio player code can be copied in different sizes:
144p, 240p, 360p, 480p, 540p, Other


 
The audio player code can be used without the image as follows:


 
This audio file can be linked to by copying the following URL:


 
Download the audio file.
 
Subscribe:
Connected Social Media - iTunes | Spotify | RSS Feed | Email
Tech Tonics - iTunes | Spotify | RSS Feed | Email
 

Her illustrious career has taken her from clinician to biotech executive to university chancellor to CEO of the world’s largest foundation, yet throughout this exceptional journey, Susan Desmond-Hellmann has remained empathetic, inquisitive, and emphatically true to herself.

Growing up in Reno, Nevada as one of seven children, Sue was inspired by her father, a pharmacist, and her mother, a teacher; she said she always wanted to be a doctor, but even so, she could not have predicted the direction and velocity of her subsequent career.

In today’s far-ranging discussion, Sue talks about how she discovered her passion for oncology; her introduction to and involvement in the HIV-AIDS crisis; how she and her husband Nick have supported each other across the ups and downs of their often-overlapping careers; their transition to pharma; her return to academia at UCSF after an exceptional decade and a half in industry; and. now as CEO of the Bill and Melinda Gates Foundation, her perspective on the future of public health — a view that leverages quantitative data and focuses on precision and personalization.

This is a captivating conversation that touches on translational research, executive leadership, and public health, as well as the person behind the success story.  David and I spoke to Sue from her home in Washington State and were thrilled to have her on the show.

Today’s episode is sponsored by IDEA pharma, the industry’s leading path-to-market strategy practice, bring more medicines to patients.  You can find them at:
ideapharma.com.

Show Notes:

This is the commentary about orphan drugs cited by David.

This Forbes column from David asks how to leverage data and analytics (as Sue proposes) without fetishizing them.

Tags: , , , , , , , , , , , , , , , ,
 
Posted in: Audio Podcast, Healthcare, Tech Tonics, Technology